The biogenesis and biological function of PIWI-interacting RNA in cancer.

Introduction

Small non-coding RNAs, a type of non-coding RNA (ncRNA), are divided into several main types, such as microRNAs (miRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), PIWI-interacting RNAs (piRNAs), and transfer RNAs (tRNAs) [ 1 ]. Numerous small ncRNAs have been widely reported to have vital roles in the pathogenesis and treatment of human cancers. Among these, piRNAs, which have a length of 24–31 nucleotides, are the least investigated class of small RNAs. The precursors of piRNAs are derived from tandem repeat sequences called piRNA clusters and form a mature piRNA/PIWI complex via two routes dependent or independent “Ping-Pong” amplification pathways [ 2 ]. piRNAs were initially identified as highly expressed in germline cells and able to silence transposons to maintain genome integrity and thereby protect the genome against transposon-induced defects in gametogenesis and fertility [ 3 , 4 ]. In addition, it has been reported that piRNAs are also widely expressed in somatic cells [ 5 ] and play regulatory roles, such as silencing the transcriptional gene process, regulating translation and mRNA stability, maintaining stem cell functions, and interacting with multiple proteins [ 6 ]. These affluent regulatory mechanisms of piRNAs in both germ and somatic cells greatly expand the scope of the existence of piRNAs and attract the interest of scientists. An increasing number of researchers are attempting to explore the mechanism of piRNAs in tumorigenesis and their application prospects in tumor diagnosis and treatment.

It has been reported that piRNAs are involved in the occurrence of numerous cancers, including renal cell carcinoma, prostate carcinoma, and diffuse large B-cell lymphoma [ 7 – 10 ]. In addition, piRNAs act as potential diagnostic markers in the early diagnosis for lung cancer, colorectal cancer, and gastric cancer [ 11 – 16 ]. piRNAs are also important prognostic indicators for kidney cancer and colorectal cancer after treatment [ 7 , 17 – 19 ]. piRNAs have also been found to affect the survival of tumor cells exposed to chemotherapy drugs and may act as novel therapeutic targets for human cancer [ 20 – 22 ]. Therefore, exploring the molecular mechanism of piRNAs in the process of tumorigenesis can provide new insights into therapeutic targets and research on drug resistance.

This review will systematically summarize the research progress toward understanding the biogenesis and biological functions of piRNA and the relevant bioinformatics databases with the aim of providing information for cancer diagnosis and therapeutics.

Biogenesis mechanisms and characteristics of piRNAs

The generation of primary piRNAs

Research on piRNA biogenesis mechanisms is increasing but remains insufficient [ 23 – 25 ]. Primary piRNAs originate from specific genomic loci called piRNA clusters in which piRNAs line up end-to-end or overlap slightly in a strand-specific manner, and a large fraction of piRNAs can be uniquely mapped to these clusters [ 2 ]. More than 90% of the piRNAs are directly derived from the piRNA clusters [ 3 , 26 ]. In general, it has been confirmed that piRNAs can be classified into five groups based on origin: transposon-derived, mRNA-derived, transfer RNA (tRNA)-derived, long noncoding RNA (lncRNA)-derived, and snoRNA-derived piRNAs (Fig. 1 A). Transposon-derived piRNAs originate from single-strand clusters transcribed, generating both sense and antisense piRNAs [ 27 ]. piRNAs derived from mRNAs originate from mRNA 3′ untranslated regions (3′UTRs) and recognize the mRNA from which they are processed [ 28 ]. tRNA-derived piRNAs are produced from 5′-tRNA halves and not mature tRNAs [ 29 – 31 ]. piRNAs derived from lncRNAs are produced from lncRNA exonic regions [ 32 ]. snoRNA-derived piRNAs are processed from snoRNAs cleaved by the middle of their sequences, containing C/D boxes and C'/D’ boxes [ 33 , 34 ]. The C box (UGAUGA) and D box (CUGA) are two conserved motifs unique to snoRNA and indispensable parts of snoRNA positioning and processing, while the C’ box and D’ box are called antisense boxes and located in the middle of the C/D box. These boxed C(C′)/D(D′) motifs are critical for protein binding and required for the function of this class of piRNAs [ 35 ]. However, the generation and shearing mechanisms and auxiliary proteins of primary piRNAs are still unclear and need further study. Fig. 1 Biogenesis mechanisms and characteristics of piRNAs. ( A ) Five origins of primary piRNAs. It has been confirmed that the generation of piRNAs can be divided into five groups depending on their origin: (a) transposon-derived, (b) mRNA-derived, (c) tRNA-derived, (d) lncRNA-derived, and (e) snoRNA-derived piRNAs. ( B ) Sense and antisense transcripts of the primary piRNAs are produced by small nucleotide sequences from clusters of piRNA genes. ( C ) Primary piRNAs are cleaved by Zuc in the YB body, and the 5′ fragments of the intermediate sequence interact with a PIWI protein to form the piRNA/PIWI complex and thus intermediate piRNAs. The 2′-hydroxyl at the 3′-end of the intermediate piRNA is methylated by Hen1 to form a mature piRNA/PIWI complex. ( D ) The primary piRNA binds to AGO3 or AUB proteins through the “ping-pong cycle” to form complexes in the nucleus. Given the complementary piRNA sequences of these two complexes, the piRNA/AGO3 complex splits target RNA in the cytoplasm to produce corresponding new sequences, which can then be used as substrates to bind to AUB proteins in the nucleus to form new piRNA/AUB complexes. TSS transcription start site; Zuc zucchini

Two routes produce mature piRNAs

Precursor piRNAs are produced from genomic sources and then transferred from the nucleus to the cytoplasm. After being cleaved and modified, the intermediate piRNAs then form mature piRNAs in a complex with PIWI proteins [ 36 ]. The processes are complex and have not been intensively studied, but the following two major pathways have been described: the primary amplification pathway and the “Ping-Pong” amplification pathway (Fig. 1 ).

The primary amplification pathway produces sense and antisense transcripts from small nucleotide sequences from clusters of piRNA genes (Fig. 1 B). After being exported to the Yb body in the cytoplasm, these primary piRNAs are cleaved by Zucchini (Zuc), an endoribonuclease enzyme [ 37 , 38 ]. Then, the 5′ fragment of the intermediate sequences interacts with a PIWI protein to form a piRNA/PIWI complex, known as the intermediate piRNAs. An exonuclease or Zuc trims the 3′-end of the piRNA to its mature length, and the 2′-hydroxy group at the 3′-end is methylated by HEN1 to subsequently yield the mature piRNA/PIWI complex [ 24 , 27 , 39 ]. Finally, the complexes block target gene transcription by migrating back to the nucleus (Fig. 1 C) [ 40 , 41 ].

The “Ping-Pong” amplification pathway serves as the second mechanism for producing many piRNAs in the cytoplasm (Fig. 1 D) [ 27 , 42 ]. piRNAs bind to AGO3 or AUB proteins rather than PIWI proteins to form piRNA/AGO3 or piRNA/AUB complexes in the nucleus. The AUB-bound piRNAs showed a 5′ bias for U, whereas AGO3-bound piRNAs featured an A at position 10 [ 43 , 44 ]. These two types of complexes contain mutually complementary piRNA sequences. Thus, a piRNA/AGO3 complex will cut the target RNA to synthesize a new sequence in the cytoplasm and then serve as a substrate for forming a piRNA/AUB complex with the AUB protein in the nucleus. Similar to the previous process, piRNA/AUB protein complexes will migrate from the nucleus to the cytoplasm and cut the complementary RNA sequence, resulting in the generation of new RNA substrates that form new piRNA/AGO3 complexes [ 45 ]. This interesting amplification loop is called the “Ping-Pong” amplification pathway [ 25 , 46 ].

Characteristics of piRNAs

At present, the relevant databases have estimated that the human genome has nearly 23,000 piRNAs, markedly higher than that of miRNAs (approximately 2000) but similar to that of proteins encoded by mRNA genes (approximately 20,000) [ 47 , 48 ]. The abundance of piRNAs reveals that piRNAs may play a role in gene regulation, similar to other small ncRNAs.

The differences between piRNAs and other small ncRNAs in humans are shown in Table 1 . piRNAs, small interfering RNAs (siRNAs), and miRNAs are three major groups of regulatory small ncRNAs. These groups with different modes of biogenesis and target regulation share some common features, such as their abilities to guide Argonaute proteins to target nucleic acids in a sequence-dependent manner [ 24 ]. However, piRNAs have three unique features that distinguish them from their counterparts. First, piRNAs are generated from intergenic regions (known as piRNA clusters) through a Dicer-independent mechanism. Second, unlike siRNAs and miRNAs, which has double-stranded transcriptional precursors, the precursors of piRNAs are single-stranded transcripts. Finally, piRNAs show 2′-O-methyl modification at the 3′-end and specifically bind to PIWI proteins to perform their corresponding function in the human body [ 49 ]. Table 1 Differences between piRNAs and other small ncRNAs in humans Characteristics piRNA miRNA siRNA Length 24–31 nt 18–25 nt 21–23 nt Small RNA precursors Single-stranded RNA Hairpin RNA Double-stranded RNA/hairpin RNA 3′ end features 2′-O-methylation No methylation 2′-O-methylation/No methylation Generation mechanism Dicer-independent Dicer-dependent (asymmetric processing) Dicer-dependent (symmetric processing) Function mRNA and transposon repression, DNA methylation, histone modification, protein interaction mRNA repression mRNA repression Associated proteins PIWI/PIWI-like/AGO/AUB AGO1-4 AGO1-4 Silencing mechanism Transcriptional and posttranscriptional Posttranscriptional Transcriptional Major target genes Transposons and other genes Coding genes Transposons and exogenous genes

Regulatory mechanisms and biological functions of piRNAs

To date, extensive research has elaborated the functions of piRNAs in animal germ cells [ 2 , 50 ], and the studies show that piRNAs maintain the genomic integrity of germ cells by inhibiting the activity of transposable elements (TEs) [ 51 ]. In human genetic diseases, including cancers, the phenomenon of TE silencing has also been reported [ 52 , 53 ]. Some studies have shown that piRNAs can guide transposon inhibition, recognize a large number of complementary sequences, achieve transcriptional silencing through epigenetic mechanisms [ 41 , 54 ], and achieve posttranscriptional inhibition via the formation of piRNA/PIWI complexes [ 36 ], thereby regulate cancer progression at multiple omics levels.

piRNA/PIWI complexes mediate target gene silencing at the transcriptome level

Given that many different PIWI proteins and effectors bind to piRNAs and that the target regulation patterns of piRNA/PIWI complexes are also diverse, there are two mechanisms through which piRNA/PIWI complexes regulate gene transcription. One is transcriptional gene silencing (TGS), which mainly occurs with PIWI proteins with low catalytic activity (Fig. 2 A) [ 55 , 56 ]. In TGS, the piRNA/PIWI complex mediates chromatin silencing by collaborating with histone-modifying enzymes or DNA methyltransferases and thereby suppresses mRNA transcription [ 2 , 57 , 58 ]. Epigenetic modification has a special role in tumorigenesis, and ncRNAs, particularly young piRNAs, play an important role in epigenetic modification [ 59 ]. A recent study found that in mouse fetal gonocytes, SPOCD1, a nuclear protein expressed only during the de novo genomic methylation period that acts as a Miwi2-related factor, binds Miwi2 to the transcripts of nascent TEs and recruits suppressive chromatin remodeling activities and de novo methylation devices [ 60 ]. Zhang et al. [ 9 ] elucidated that the piR-31470/PIWIL4 complex could regulate the methylation level of GSTP1 by recruiting multiple DNA methylation enzymes, thus promote prostate cancer progression. Moreover, in multiple myeloma cells, piRNA-823 could cause aberrant DNA hypermethylation and induce carcinogenesis by DNMT3B activation [ 61 , 62 ]. In esophageal squamous cell carcinoma (ESCC) tissues, upregulated piR-823 may play a tumorigenic role by inducing abnormal DNA methylation of DNMT3B through epigenetic inheritance [ 63 ]. Fig. 2 Regulatory mechanisms and biological functions of piRNAs and piRNA/PIWI complexes. ( A ) TGS mainly occurs on PIWI proteins with low catalytic activity. The role of piRNAs in gene expression modification is similar to that of DNA methylation. ( B ) PTGS usually requires PIWI proteins to perform cleavage because it depends on target transcriptional fragments. Here, piRNAs play a role similar to that of miRNAs. ( C ) Both piRNAs and PAZ domains of PIWI proteins in the piRNA/PIWI complex can directly bind to some proteins and thus promote multiprotein interactions

Another mechanism is posttranscriptional gene silencing (PTGS), in which PIWI proteins are usually needed to perform cleavage because PTGS depends on target transcriptional fragments (Fig. 2 B) [ 55 , 64 , 65 ]. piRNAs regulate posttranscriptional networks by interacting with RNAs, including mRNAs [ 66 ], transcribed pseudogenes [ 22 ], and lncRNAs [ 67 ], and play a role similar to that of miRNAs. Peng et al. [ 66 ] found that piR-55490 could bind to the 3′UTR of mTOR , induce mRNA degradation, and thus promote lung cancer progression.

piRNA/PIWI complexes interact with proteins at the proteome level

Both piRNAs and the PAZ domains of PIWI proteins in the piRNA/PIWI complex can directly bind to some proteins and promote multiprotein interactions (Fig. 2 C). For example, piR-823, which inhibits heat shock protein (HSP) expression, binds to HSF1, a common transcription factor of HSPs, and thus promotes phosphorylation at Ser326 in colorectal cancer [ 68 ]. Another study revealed that the piR-54265/PIWIL2 complex could recruit STAT3 and P-SRC via the PAZ domain of PIWIL2, form the PIWIL2/STAT3/P-SRC complex, promote STAT3 phosphorylation and signaling pathway activation, and finally contribute to colorectal tumorigenesis [ 19 ].

piRNAs related to cancer hallmarks

To date, dozens of aberrantly expressed piRNAs have been identified to be involved in the occurrence and progression of cancer (Fig. 3 ). Their functions and mechanisms can be summarized in terms of several representative hallmarks of cancer. The cancer hallmarks summarize the carcinogenic process behind the main phenotypic changes observed in cancer [ 69 ]. These changes overcome the original anticancer defense mechanisms in cells and tissues. In 2011, the originally identified hallmark changes were updated to mainly include sustained proliferative signaling, avoidance of immune destruction, tumor-promoting inflammation, angiogenesis induction, evasion of growth suppressors, acquisition of replicative immortality, activation of invasion and metastasis, resistance of cell death, and deregulation of cellular energetics [ 70 ]. For example, the well-known piRNA piR-823 affects the progression of colorectal cancer, gastric cancer, ESCC, and hematological malignancy through multiple pathways, such as tumor cell proliferation, apoptosis, angiogenesis, and energy metabolism [ 14 , 61 , 63 ]. To elucidate the specific mechanisms through which piRNAs lead to tumorigenesis, we classified the reported piRNAs according to their role in cancer hallmarks (Fig. 3 ) and elaborated their functions in detail. Fig. 3 piRNAs involved in human cancers. piRNAs related to cancer hallmarks are shown in the circle. The other five tumor hallmarks (genome instability and mutation, avoidance of immune destruction, evasion of growth suppression, acquisition of replicative immortality, and tumor-promoting inflammation) were not found to involve piRNAs. Other aberrant piRNAs in human cancers are shown in the box. The piRNAs shown in black have an oncogenic role, the piRNAs in blue have a tumor-suppressive role, and those shown in yellow have reportedly controversial roles in the specific cancer type. Abbreviations: DLBCL, diffuse large B-cell lymphoma. a Different studies of piR-823 in specific cancer types

Sustained proliferative signaling

Most studies suggest that abnormal piRNA expression may result in the uncontrolled proliferation of cancer cells [ 11 , 12 , 14 , 61 , 68 , 71 – 76 ]. Tumor cells deregulate chronic proliferative signals and then activate classic signaling pathways, such as the PI3K/AKT/mTOR signaling pathway, to regulate cell cycle progression and cell growth to meet the needs of unlimited cell replication and proliferation [ 77 , 78 ]. Hence, the expression of piR-004800 has been found to be regulated by the sphingosine-1-phosphate receptor and thus activates or inhibits the PI3K/AKT/mTOR signaling pathway [ 79 ]. The cooperation of downregulated piR-004800 and the PI3K/AKT/mTOR signaling pathway restrains cellular growth in exosomes from bone marrow supernatants of patients with multiple myeloma. Moreover, in multiple myeloma cell lines, the silencing of piR-004800 induces apoptosis in vitro and in vivo. Small RNA transcriptome sequencing revealed that the expression of piR-Hep1 is upregulated in 46.6% of hepatocellular carcinoma tumors compared with adjacent non-tumoral liver tissue [ 80 ]. The silencing of piR-Hep1 using a locked nucleic acid (LNA) inhibitor suppresses cell viability and motility. Mechanistically, piR-Hep1 interacts with PIWIL2 to form the piR-Hep1/PIWIL2 complex, and this complex activates the PI3K/AKT pathway and regulates cellular proliferation, survival, and metabolism via protein phosphorylation. In lung cancer, Peng et al. [ 66 ] observed that piR-55490 is downregulated in lung carcinoma tissues and cells. Intriguingly, silenced piR-55490 promotes the growth of lung cancer by binding to the mTOR 3′UTR and activating the AKT/mTOR pathway. The overexpression of piR-55490 in a lung carcinoma xenograft model results in the inhibition of tumor growth. Additionally, one study found that piR-36712 may affect breast cancer cell proliferation but not apoptosis by suppressing the selenoprotein W1 ( SEPW1 ) levels through its pseudogene SEPW1P in either MCF-7 or ZR75-1 cells [ 22 ]. In colorectal cancer, Weng et al. [ 18 ] showed that the downregulation of piR-1245 is indispensable for activation of the P53 pathway. After the silencing of piR-1245 in HCT116 and SW480 cells, a particular effect has been observed on the suppression of proliferation and the induction of apoptosis. All piRNAs confirmed to be capable of regulating cellular proliferation in cancer are shown in Fig. 3 .

Resistance to cell death or apoptosis

Apoptosis is one form of cell death. It is critical to explore the biological regulatory mechanisms in the process of tumor apoptosis regarding the malignant development, metastasis, and drug resistance of tumors [ 81 , 82 ]. In addition, small molecules associated with the apoptotic pathway have been employed in cancer therapies [ 83 , 84 ]. Using a piRNA molecular beacon, a previous study revealed that the upregulation of piR-36026 inhibits the gene expression of SERPINA1 and LRAT , which are known for their tumor-suppressing functions, and then promotes cell proliferation and inhibits apoptosis in breast cancer [ 85 ]. He et al. [ 34 ] found that the overexpression of snoRNA-derived piRNA piR-sno75 in breast cancer cells could upregulate TRAIL, a classic apoptotic protein. Mechanistically, piR-sno75 recruits the MLL3/compass-like complex to induce H3K4 methylation and H3K27 demethylation in the promoter region of TRAIL and triggers exogenous apoptosis pathways by interacting with DR4 and DR5. Chu et al. utilized piRNA microarray technology to determine the overall expression of piRNAs in three groups of bladder cancer and adjacent tissues. The results indicated that the piRNA DQ594040 is downregulated in bladder cancer and that the overexpression of DQ594040 could inhibit the proliferation and reduce the apoptosis of bladder cancer cells [ 86 ]. The downregulation of piR-39980 significantly attenuates apoptosis of the HT1080 fibrosarcoma cell line and functions as a tumor suppressor [ 87 ]. Through a flow cytometric cell cycle analysis, DAPI staining, and acridine orange/ethidium bromide (AO/EB) dual staining, the authors also found that piR-39980 induces proliferation in fibrosarcoma cells. Conversely, piR-39980 is upregulated in neuroblastoma and osteosarcoma cell lines, and the transient overexpression of piR-39980 plays an oncogenic role and promotes tumor progression without affecting the classical apoptosis pathway [ 20 , 88 ].

Activation of invasion and metastasis

The enhancement of tumor cell invasion and migration is closely relevant to the malignant progression of tumors and is also an important process in tumor development. Three piRNAs (piR-57125, piR-38756, and piR-30924) exhibit a strong association with tumor metastasis in genome-wide microarray and RT-qPCR analyses of clear cell renal cell carcinomas [ 89 ]. In prostate cancer, piR-001773 and piR-017184 synergistically regulate the transcription of protocadherin 9 ( PCDH9 ) under homeostasis and thereby promote tumor invasion and metastasis [ 90 ]. Another study showed that the cooperation of PIWIL3, piR-30188, OIP5-AS1, and miR-367-3p regulates the migration and invasion of glioma cells. Their target gene, CEBPA , regulates TNF receptor-associated factor 4 and PIWIL3 and forms a feedback loop to control cellular growth [ 67 ].

Angiogenesis induction

In general, tumor angiogenesis strengthens the interaction between blood vessels and tumor cells to lead to tumor growth and metastasis [ 91 ]. Few studies have investigated the role of piRNAs in promoting tumor angiogenesis, and most of these have focused on piRNA-823 [ 61 , 62 , 72 ]. In multiple myeloma, piRNA-823 may promote tumorigenesis by regulating de novo DNA methylation and angiogenesis [ 61 ]. Mechanistically, piRNA-823 induces a decrease in VEGF secretion to reduce proangiogenic activity among multiple myeloma cells. The VEGF pathway could play a neoangiogenic function in multiple myeloma cells in a paracrine manner and thus promotes the occurrence of tumors. Another mechanistic study showed that granulocytic myeloid-derived suppressor cells (G-MDSCs) induce piRNA-823 expression to enhance the tumorigenicity of multiple myeloma cells through DNA methylation [ 62 ]. In addition, the inhibition of piRNA-823 in multiple myeloma cells decreases the stemness of multiple myeloma stem cells preserved by G-MDSCs and reduces the tumor burden and angiogenesis in vivo. Li et al. [ 72 ] revealed that piRNA-823 delivered by multiple myeloma-derived extracellular vesicles contributes to the invasion of endothelial cells by regulating the ICAM-1 and CXCR4 levels.

Deregulation of cellular energetics

The main feature of tumors is the rapid proliferation of cells. During the process of rapid proliferation, energy metabolism is needed to promote cell growth and division [ 70 ]. Therefore, excessive energy and metabolic reprogramming, which are regulated by various carcinogens and tumor suppressors, are important parts of human cancer that differentiate cancer from normal tissues [ 92 ]. For example, Feng et al. [ 14 ] found that upregulated piRNA-823 in colorectal cancer cells could inhibit the ubiquitination of hypoxia-inducible factor-1 ( HIF-1 ) by increasing the expression of glucose-6-phosphate dehydrogenase ( G6PD ), and this inhibition increases glucose consumption in cancer cells and reduces the intracellular reactive oxygen species content.

DNA damage and aging

DNA damage is a permanent change in DNA nucleotide sequence that occurs during replication. DNA sequence polymorphisms caused by a single nucleotide mutation at the genome level are called single nucleotide polymorphisms (SNPs), and these SNPs may also lead to DNA damage. SNPs increase the susceptibility to cancer mainly through two routes. On the one hand, SNPs in piRNA biogenesis pathway-related genes may alter the process of piRNA production, affect piRNA maturation and expression [ 93 , 94 ]. Genes that have an important influence on the process of piRNA production are called piRNA biogenesis pathway-related genes. The core effector complex of the piRNA biogenesis pathway is mainly composed of piRNAs and proteins in the PIWIL protein subfamily (HIWI/PIWIL1, HILI/PIWIL2, HIWI3/PIWIL3, and HIWI2/PIWIL4) [ 95 ]. The PIWI protein family and related factors play a vital role in various cellular processes and diseases, and the genetic variations that occur in these genes have the potential to regulate the function of piRNAs. Zhang et al. [ 96 ] found that the tag SNP rs11551405 in DCP1A , which is a piRNA biogenesis pathway-related gene, is associated with an increased risk of melanoma-specific death. On the other hand, SNPs may not change the maturation and expression of piRNA, but affect the interaction of piRNA with other RNAs or proteins, thus affect the risk of tumor development. Another study revealed that the SNP rs11776042 may be involved in the generation of piR-015551 from LNC00964-3, which is significantly associated with a decreased risk of colorectal cancer [ 97 ].

Additionally, aggregation of DNA damage causes aging, making normal cells less efficient and inevitably leading to disease or cancer [ 98 ]. The regulation of TEs by piRNAs can affect DNA damage through aging speed [ 99 ]. A study showed that piR-39980 could induce neuroblastoma cellular senescence by changing the regulation of JAK3 expression through a route independent of classical apoptosis pathways [ 20 ].

Overall, the discovery of small ncRNAs has led to profound alterations in our perceptions of the mechanisms of gene control in cancer. To date, most of the functional studies on piRNAs have focused on the effects on tumor cell characteristics, such as the effects on tumor cell proliferation, apoptosis, invasion, and metastasis. However, these only scratch the surface of the real complexity, and the detailed mechanisms in tumors have not been thoroughly studied. In particular, whether piRNAs can affect other cancer hallmarks, such as avoidance of immune destruction or tumor-promoting inflammation, is worth exploring in the future.

piRNAs as diagnostic and prognostic biomarkers in cancer

Tumor screening is an important approach for the early detection of cancer and precancerous lesions [ 100 – 102 ]. Small RNAs such as miRNAs have received abundant attention as potential noninvasive biomarkers for early cancer screening [ 103 ]. piRNAs can also be used as biomarkers for cancer screening. For example, piR-54265 is a molecular marker for early colorectal cancer screening in the general population [ 104 ]. Additionally, the study of clinical prognostic indicators is valuable for improving the life quality of patients with cancer. Most studies have focused on the application of piRNAs as diagnosis and prognostic markers for patients with cancer. The clinical applications of piRNAs as potential diagnostic and prognostic biomarkers in a variety of cancers are shown in Table 2 . Table 2 Clinical applications of piRNAs in cancer piRNA Cancer Sample type Expression in tumors Diagnosis biomarker Prognostic biomarkers Chemoresistance Therapeutic targets Clinical relevance References piR-36712 Breast cancer Tissues ↓ √ √ √ √ Metastatic [ 22 ] piR-932 Cell lines ↑ – [ 108 ] piR-4987 Tissues ↑ √ Metastatic [ 113 ] piR-20365 Tissues ↑ √ – [ 113 ] piR-20485 Tissues ↑ √ – [ 113 ] piR-20582 Tissues ↑ √ – [ 113 ] piR-sno75 Cell lines/tissues ↓ √ √ – [ 34 ] piR-10506469 CHOL Plasma exosomes ↑ √ – [ 105 ] piR-24000 Colorectal Cancer Tissues ↑ √ Metastatic, differentiation, tumor stage [ 13 ] piR-020619 Serum ↑ √ – [ 107 ] piR-020450 Serum ↑ √ – [ 107 ] piR-54265 Serum ↑ √ √ Tumor stage, relapse [ 104 ] piR-823 Tissues ↑ √ √ Metastatic, tumor stage, Adjuvant chemotherapy [ 14 , 68 ] piR-017724 Serum ↓ √ – [ 109 ] piR-18849 Tissues ↑ √ Metastatic, differentiation [ 17 ] piR-19521 Tissues ↑ √ Metastatic, differentiation [ 17 ] piR-1245 Tissues ↑ √ Metastatic [ 18 ] piR-54265 Tissues ↑ √ √ √ – [ 19 ] piR-5937 Serum ↓ √ – [ 114 ] piR-28876 Serum ↓ √ – [ 114 ] piR-30473 DLBCL Tissues ↑ √ – [ 10 ] piR-823 ESCC Tissues ↑ √ √ Metastatic [ 63 ] piR-10506469 Gallbladder carcinoma Plasma exosomes ↑ √ Tumor stage [ 105 ] piR-1245 Gastric cancer Gastric juice ↑ √ Tumor stage, tumor size [ 15 ] piR-823 Tissues ↓ √ – [ 71 ] piR-651 Tissues ↑ √ √ – [ 16 ] piR-8041 Glioblastoma Tissues ↓ √ √ – [ 112 ] piR-30188 Tissues ↓ √ – [ 67 ] piR- DQ593109 Glioma Cell lines ↑ √ – [ 118 ] piR-651 Hematological malignancy Serum ↑ √ – [ 21 ] piR-823 Cell lines ↑ Tumor stage [ 61 ] piR-823 Cell lines ↑ √ Tumor stage [ 72 ] piR-004800 Cell lines/exosomes ↑ √ – [ 79 ] piR-34736 HNSCC Tissues ↑ √ – [ 116 ] piR-34536 Kidney cancer Tissues/serum ↓ √ – [ 110 ] piR-51810 Tissues/serum ↓ √ Metastatic [ 110 ] piR-32051 Tissues ↑ √ – [ 7 ] piR-43607 Tissues ↑ √ – [ 7 ] piR-39894 Tissues ↑ √ Metastatic [ 7 ] piR-57125 Tissues ↓ √ Relapse [ 89 ] piR-30924 Tissues ↑ √ Relapse [ 89 ] piR-38756 Tissues ↑ √ – [ 89 ] piR-823 Tissues ↓ √ – [ 115 ] piR-651 Lung cancer Tissues ↑ √ √ Tumor stage, relapse [ 11 , 12 ] piR-55490 Tissues ↓ √ – [ 66 ] piR-L-138 Cell lines ↑ √ [ 111 ] piR-39980 Neuroblastoma Cell lines ↑ √ – [ 20 ] piR-017061 pancreatic cancer Tissues ↓ √ – [ 117 ] piR-21238 PTC Tissues ↑ √ Tumor stage [ 106 ] piR-13643 Tissues ↑ √ Tumor stage [ 106 ] CHOL cholangiocarcinoma, DLBCL diffuse large B-cell lymphoma, ESCC esophageal squamous cell carcinoma, HNSCC head and neck squamous cell carcinoma, PTC papillary thyroid carcinoma

In both patients with cholangiocarcinoma and patients with gallbladder carcinoma, the expression of piR-10506469 in blood one week after surgery is significantly decreased compared with that before surgery [ 105 ]. Similarly, the level of piR-10506469 in patient plasma exosomes is significantly increased compared with that in healthy individuals, which suggests its unique diagnostic value. In ESCC, piR-823 is positively correlated with DNMT3B expression [ 63 ]. The authors revealed that the carcinogenic effect of piR-823 may result from its induced abnormal DNA methylation via DNMT3B . Additionally, an increased risk of lymph node metastasis is associated with a higher piR-823 level, and piR-823 exhibits high specificity for detecting ESCC (AUC = 0.713), which suggests its potential as a diagnostic and prognostic biomarker. In NSCLC, piR-651 can induce tumor progression by affecting the cyclin D1 / CDK4 pathway and acts as a potential diagnostic indicator [ 11 , 12 ]. Using piRNA sequencing data from papillary thyroid carcinoma (PTC), researchers have identified two upregulated piRNAs, piR-13643 and piR-21238 and found that these two piRNAs are associated with clinical stages and exhibit better specificity for distinguishing between benign and malignant nodules than the current biomarker HBME1 [ 106 ].

Interestingly, the expression of piR-1245 in gastric juice is higher in patients than in control individuals, with an AUC value of 0.885 [ 15 ]. Moreover, the expression of piR-1245 in gastric juice has the potential to be a noninvasive biomarker for gastric cancer detection and prognosis. In another study, the well-known piRNA piR-651 was found to be a potential marker for gastric cancer diagnosis [ 16 ]. In colorectal cancer, piR-24000 acts as a possible oncogene that can significantly distinguish patients with colorectal cancer from normal individuals [ 13 ]. Additionally, serum piR-54265, piR-020619, and piR-020450 were also found to serve as sensitive and specific noninvasive biomarkers for early colorectal cancer detection in previous studies [ 104 , 107 ]. Another research group used a piRNA microarray to identify a well-known oncogenic piRNA, piRNA-823, which is highly expressed in colorectal cancer tissues [ 14 ]. In this study, the authors performed multivariate analysis and found that piRNA-823 is an independent predictor of overall survival, which suggests its important role in colorectal cancer carcinogenesis. Furthermore, piR-19521, piR-18849, and piR-1245 also show novel independent prognostic characteristics and have the potential to be used as prognostic markers in colorectal cancer [ 17 , 18 ].

In addition to the above-mentioned piRNAs, piRNAs that have been clinically correlated with breast cancer, lung cancer, kidney cancer, and glioblastoma are shown in Table 2 [ 34 , 108 – 118 ]. Given the activation of piRNAs in germline cells, abnormal expression of piRNAs is more sensitive to the diagnosis of testicular cell tumors compared with that of other small ncRNAs [ 119 ]. Moreover, the expression of piRNAs in circulation is relatively stable and is easily detected in body fluids, such as blood, serum, or gastric juice. Thus, piRNAs may have great potential for early non-invasive cancer screening in the general population and diagnosis in patients with cancer, but there still remain some disadvantages to the efficiency of piRNAs. First, some piRNA tests using patient’s tissues, which can be harmful to patients, are still needed for diagnosis. Second, compared with the existing tests, the detection and identification of piRNAs in tissue or body fluids are more expensive, which restricts the extensive use of piRNAs as biomarkers. Third, the reliability of using piRNAs for diagnosis still needs to be proven.

piRNAs and cancer therapy resistance

Cancer therapies mainly include radiotherapy and chemotherapy. The combination of targeted therapy and chemotherapy significantly prolongs the overall survival of patients with advanced disease and improves their quality of life [ 120 ]. However, primary or acquired drug resistance ultimately results in therapeutic failure and poor prognosis in cancer patients [ 121 ]. Therefore, the development of new strategies is urgently needed to improve therapeutic responses. Many mechanisms, including reduced drug accumulation, enhanced DNA repair, a favorable tumor microenvironment (TME) and target gene amplification, have been proven to be involved in therapy resistance, and piRNAs may be a novel therapeutic target for human cancer [ 122 – 124 ]. In recent years, the role of multiple ncRNAs in regulating metastasis and recurrence of malignancies has received increased attention [ 14 , 125 – 128 ]. Nevertheless, studies of piRNAs in cancer therapy, particularly in cancer resistance to radiotherapy or chemotherapy, are still at the nascent stage. The specific mechanism through which piRNAs affect resistance is related to chemotherapy-induced decreases in apoptosis, which makes tumor cells insensitive. This section highlights the functions of piRNAs in modulating therapy resistance in different cancers and discusses the limitations of the available knowledge and future potential directions.

In detail, piR-39980 has been identified as a key contributor to chemoresistance to doxorubicin in neuroblastoma cells and inhibits drug-induced apoptosis [ 20 ]. In the study, the researchers transfected IMR-32 cells with piR-39980 at different concentrations of doxorubicin and then measured the viability of the cells. Compared with cells treated with a single drug, cells overexpressed piR-39980 exhibited reduced sensitivity to doxorubicin, which might have led to the development of drug resistance. Another study examined the serum piR-651 levels in 94 patients with classical Hodgkin lymphoma and found that lower levels of piR-651 are related to increased overall and disease-free survival and complete response to first-line treatment [ 21 ]. Tan et al. [ 22 ] revealed that the overexpressed piR-36712 in ZR75-1 and MCF7 cells markedly reduces the IC 50 values of doxorubicin and paclitaxel in these cells, whereas the inhibition of piR-36712 has the opposite effect, and these patterns have been confirmed in mouse xenograft models. This synergistic anticancer effect suggests that piR-36712 may be an effective agent for breast cancer treatment. Interestingly, Mai et al. [ 104 ] also found a synergistic anticancer effect of piRNAs in colorectal cancer. These authors found that the reduced apoptosis induced by chemotherapy drugs results in the insensitivity of piR-54265-overexpressed colorectal cancer cells to chemotherapy drugs. Similarly, studies using a mouse xenograft tumor model using oxaliplatin, 5-FU or a combination regimen found that subcutaneous tumors formed by colorectal cancer cells overexpressed piR-54265 exhibit increased resistance to chemotherapy, whereas subcutaneous tumors with downregulated piRNA expression show an excellent response to chemotherapy. These results suggest that targeting piR-54265 may provide a novel approach for colorectal cancer treatment.

Databases for piRNAs and functional predictions

As high-throughput sequencing technology improves, many programs have been developed to identify piRNAs from small RNA data, and these include Piano, piRNAPredictor, piRPred, 2L-piRNA, Pibomd, IpiRId, V-ELMpiRNAPred, proTRAC, piClust, and piRNN [ 129 – 138 ]. For example, piRPred is a machine learning method that uses support vector machine classifiers and multiple kernels to identify piRNAs based on four unique sequence features of piRNAs [ 131 ]. In non-model organisms, the deep learning model developed by piRNN using the convolution neural network framework exhibits better performance [ 138 ]. Subsequently, some available databases have integrated different types of piRNA data to assist the functional research of piRNAs (Table 3 ). However, due to the different naming rules and numbers of piRNA in each database, the names of piRNAs in various studies are not consistent, thus a unified naming standard should be established for the study of piRNAs. For example, hsa-piR-30025 and hsa_piRNA_30025 are listed in the piRNAdb and piRNAQuest databases, respectively, but have different chromosomal positions. In addition, there is no uniform naming strategy for piRNAs in the National Center for Biotechnology Information (NCBI) GenBank, and various data sources are included in this database. Table 3 Details of databases for piRNAs and functional predictions Databases Characteristics Organisms Website piRBase This database focuses on the comprehensive annotation of piRNA sequences and contains potential piRNA targets and disease-related piRNAs 21 organisms a) http://www.regulatoryrna.org/database/piRNA/ RNAdb 2.0 This database contains over 88,000 piRNA candidates that have been cloned and sequenced from mice, humans, and rats Human, mouse and rat http://research.imb.uq.edu.au/RNAdb/ piRNA Cluster Database This database provides comprehensive data on piRNA clusters in multiple species, tissues, and developmental stages based on small RNA sequence data deposited in NCBI’s Sequence Read Archive (SRA) 51 organisms b) https://www.smallrnagroup.uni-mainz.de/piCdb/ piRNAdb This database is a PIWI-interacting RNA sequence storage and search system that provides some other types of relevant information such as alignments, clusters, datasets, and targets of piRNAs 6 organisms c) https://www.pirnadb.org/ piRNABank This database compiles all the possible clusters of piRNAs and depicts piRNAs along with the associated genomic elements such as genes and repeats on a genome-wide map Human, mouse, rat, and Drosophila http://pirnabank.ibab.ac.in/ piRNAQuest This database provides annotation of piRNAs based on their genomic location in gene, intron, intergenic, CDS, UTR, repeat element, pseudogene, and syntenic regions. The database also contains information on all possible piRNA clusters along with significant motifs present within the piRNAs comprising a cluster Human, mouse and rat http://bicresources.jcbose.ac.in/zhumur/pirnaquest/ IsopiRBank This database stores piRNA isoforms detected from small RNA sequencing data, performs detailed classification, and integrates annotation information as well as genome mapping results. Furthermore, target analysis and enrichment analysis revealing the piRNA isoform roles in certain biological processes are included Human, mouse, Drosophila, and zebrafish http://mcg.ustc.edu.cn/bsc/isopir/ piRNA-eQTL This database demonstrates the effects of genetic variation on piRNA expression based on the Cancer Genome Atlas (TCGA) project and is a user-friendly database for the analysis of cis-piRNA eQTLs for 33 cancer types Human http://njmu-edu.cn:3838/piRNA-eQTL/ pirScan This database allows C. elegans researchers to predict piRNA-targeting sites and to avoid the persistent germline silencing of transgenes that has rendered many constructs unusable C. elegans or C. briggsae http://cosbi4.ee.ncku.edu.tw/pirScan/ piRTarBase This database allows researchers to explore piRNA-targeting sites and their regulatory effects on endogenous genes and identify predicted mRNA targets of specific piRNAs C. elegans or C. briggsae http://cosbi6.ee.ncku.edu.tw/piRTarBase/ a) 21 organisms: C. elegans, chicken, cow, crab-eating macaque, D. erecta, D. melanogaster, D. virilis, D. yakuba, human, marmoset, mouse, pig, rabbit, rat, rhesus, sea hare, silkworm, starlet sea anemone, tree shrew, X. tropicalis, and zebrafish b) 51 organisms: African clawed frog, African malaria mosquito, American alligator, Arizona bark scorpion, big brown bat, blue-eyed rice fish, brown rat, budgerigar, cabbage looper, Carolina anole, cattle (col. cow), common house spider, common marmoset, crab-eating macaque, diamondback moth, European honey bee, European rabbit, fruit fly, giant tiger prawn, goldfish, gray mouse lemur, gray short-tailed opossum, great pond snail, Herbst’s burying beetle, horse, house mouse, housefly, human, Japanese rice fish, large earth bumblebee, large milkweed bug, migratory locust, northern tree shrew, oriental fruit fly, Pacific oyster, pea aphid, pig, platypus, red flour beetle, rhesus macaque, speckled wood, three-spined stickleback, vinegar fly, West African fruit fly, western clawed frog, wolf (dog), yakuba fruit fly, yellow fever mosquito, yellowhead catfish, and zebrafish c) Six organisms: Caenorhabditis elegans, Cricetus griseus, Drosophila melanogaster, human, Mus musculus, and Rattus norvegicus

At present, piRBase is the largest and most complete piRNA database, with 264 datasets from 21 species [ 139 , 140 ], and it is an expert database in RNAcentral. Since piRBase was launched by He et al. in 2014, researchers have systematically discovered the shearing and regulatory effect of piRNAs on coding genes [ 44 ], developed a piRNA target gene prediction algorithm [ 141 ], and upgraded the database in 2018. Given the functional diversity of piRNAs, piRBase divides piRNAs into two categories according to their biogenesis: repeat-derived and gene-overlapping piRNAs. In addition, piRBase also includes epigenetic data and predicted lncRNAs and gene targets of piRNAs. Notably, the piRNA and cancer data in piRBase cover eight types of cancer (breast, bladder, pancreatic, gastric, liver, kidney, colorectal cancer, and myeloma) to assist cancer-related studies.

Another database, RNAdb 2.0, also stores more than 88,000 candidate piRNAs from mice, humans, and rats [ 142 ]. One study compared piRNA sequences with the sequences of other ncRNAs using the RNAdb 2.0 and piRNABase databases and showed that piRNAs in human plasma consist of ncRNA fragments that are the same as those in human tumor tissues [ 143 ]. The piRNA Cluster Database provides comprehensive data on piRNA clusters based on tissues from 12 species and developmental stages [ 144 ]. piRNAdb, which was developed by The Bioinformatics Laboratory at the Molecular Oncology Center in Brazil, provides other relevant information, such as alignments, clusters, datasets, and targets of piRNAs.

Additionally, piRNABank, originally founded by Lakshmi et al. [ 47 ], is a network resource with classified and clustered piRNAs. The database is a user-friendly resource that stores comprehensive information about piRNAs from humans, mice, rats, and Drosophila. It includes all possible piRNA clusters and supports a comprehensive search function for organisms and chromosomes, including accession numbers, chromosomal locations, gene names or symbols, sequence homology-based searches, clusters, and corresponding genes and repeating elements. Another database, piRNAQuest, also contains information about all possible piRNA clusters [ 145 ]. Detailed classifications of piRNA isoforms detected by small RNA sequencing data are included in IsopiRBank [ 146 ]. This database can be used to reveal the role of piRNA isomers in some biological processes through target analysis and enrichment analysis. The other two databases, pirScan and piRTarBase, contain piRNA information from Caenorhabditis elegans or Caenorhabditis briggsae [ 147 , 148 ]. Researchers have been able to predict piRNA target sites and identify expected mRNA targets of piRNAs.

In addition, our research group recently constructed a piRNA-expression quantitative trait locus (eQTL) database to reveal the effects of SNPs and piRNAs on the genetic mechanism of cancer at the genomic level [ 149 ]. Based on the genotyping and piRNA expression data of 33 cancer types in The Cancer Genome Atlas (TCGA), millions of SNP-piRNA pairs have been identified via eQTL analysis in both tumor tissues and normal tissues. This database provides the first combination of genetic variation with piRNAs, which will generate new ideas for further research on cancer etiology.

Conclusions and perspectives

Abundant studies have reported the important role of ncRNAs in the regulation of different types of cancer [ 150 , 151 ]. Compared with lncRNAs, miRNAs, and circRNAs, piRNAs are a relatively new type of ncRNA and have attracted increasing attentions in recent years. Due to the discovery that piRNAs are related to many types of tumors, their mechanisms and functions need to be explored. Although the expression of piRNAs can be easily detected through the development of next-generation sequencing technology, there remain many unknown piRNAs due to the complicated mechanisms through which they are generated, the difficulty in their identification, the lack of universal rules for piRNA naming, the instability of the detection results, and the current lack of knowledge on their regulatory mechanisms. Several limitations and perspectives are illustrated below.

As mentioned above, the three main regulatory mechanisms and biological functions of piRNAs are TGS, PTGS, and protein–protein interactions. In TGS, piRNAs appear to play a role in gene expression modification that is similar to DNA methylation. In general, piRNAs mainly affect tumor development by regulating DNA methylation transferase and then cause aberrant DNA hypermethylation. However, whether DNA methylation could reversely affect the expression or functions of piRNAs remains unclear and deserves further discussion. Moreover, the dual mechanism of the piRNA/MIWI complex in the process of mouse spermiogenesis, which involve inducing the degradation or translational activation of target mRNA via recruitment of related factors, has been investigated [ 152 , 153 ]. Similarly, whether the piRNA/PIWI complex functions through a similar dual mechanism in human tumor cells is worth investigating. Furthermore, given the base-pairing principle, the variation of a single base in the piRNA-mRNA binding domain may also disrupt piRNA function. Therefore, the effect of genetic variations in the pairing region should be sufficiently explored to identify new piRNA mechanisms in the future.

We also found that most previous studies only described the one-to-one, multiple-to-one, or one-to-multiple relationship between piRNAs and their target genes in tumors, whereas few studies have explored the combined effects of multiple piRNAs in a pan-cancer analysis. In addition, different piRNAs may perform additive or opposite functions. Therefore, the combined effects of multiple piRNAs on multiple targets in tumors should also be addressed in future studies, and the results will contribute to a more comprehensive understanding of the role of piRNAs in the pathogenesis and progression of tumors.

In addition, most of the functions of piRNAs studied to date were limited to their effects on tumor phenotypes. In the past few decades, there has been a substantial increase in the study of the mechanisms of cancer immunity. Similarly, most of the prognostic studies performed to date have focused on the effect on tumor chemotherapy resistance rather than radiotherapy or immunotherapy resistance. Whether piRNAs are involved in the individual immune processes of cancer remains unclear. The role of piRNAs in resistance to immune checkpoint blockade agents in cancers has not been investigated. Therefore, additional studies are needed to better understand the piRNA-mediated regulation of cancer immunotherapy, and the results will lead to the development of novel effective therapeutic strategies for cancer therapy.

Several recent studies demonstrated that PIWI proteins highly expressed in germ cells can still be activated in human tumor cells in the absence of piRNA induction and promote tumorigenesis in different modes [ 154 , 155 ]. Consequently, these studies have enriched the knowledge of the mechanism of piRNAs and PIWI proteins in the field of human cancer. All of this information makes it possible to induce or exogenously add piRNA as a potential therapeutic strategy for human cancer with high PIWI protein expression in the future.

In short, unlike other ncRNAs, piRNAs, as a relatively newly discovered type of small ncRNA, have rarely been the topic of preclinical studies or clinical trials. In the future, large cohort clinical studies are needed to further explore and verify the potential and advantages of piRNAs as biomarkers for tumor diagnosis, prognosis and therapeutic efficacy. Although there remain many unknown challenges, advances in multiomics, sequencing and other technologies will lead to a more in-depth and comprehensive assessment of piRNAs as a new target for tumor diagnosis and treatment.

Abbreviations

Non-coding RNA

PIWI-interacting RNAs

3′ Untranslated regions

Transposable elements

Transcriptional gene silencing

Esophageal squamous cell carcinoma

Posttranscriptional gene silencing

Heat shock protein

Locked nucleic acid

Suppressing selenoprotein W1

Acridine orange/ethidium bromide

Protocadherin 9

Granulocytic myeloid-derived suppressor cell

Hypoxia-inducible factor-1

Glucose-6-phosphate dehydrogenase

Single nucleotide polymorphisms

Papillary thyroid carcinoma

Tumor microenvironment

National Center for Biotechnology Information

Expression quantitative trait locus

The Cancer Genome Atlas

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Silu Chen, Shuai Ben and Junyi Xin have contributed equally to this work.

Acknowledgements

We thank BioRender ( https://biorender.com/ ) for the construction of the diagram.

Authors' contributions

MW, ZZ, and MD contributed to the study design, manuscript discussion and critical revision. SC, SB and JX drafted the manuscript. HW and LF assisted with the collection and visualization of the data. SL and RZ revised and polished the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by National Natural Science Foundation of China (81822039) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

No potential conflicts of interest are disclosed.

References

1. Beermann J Piccoli MT Viereck J Thum T Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches Physiol Rev 2016 96 1297 1325 10.1152/physrev.00041.2015 27535639

2. Czech B Munafo M Ciabrelli F Eastwood EL Fabry MH Kneuss E piRNA-guided genome defense: from biogenesis to silencing Annu Rev Genet 2018 52 131 157 10.1146/annurev-genet-120417-031441 30476449 PMC10784713

3. Girard A Sachidanandam R Hannon GJ Carmell MA A germline-specific class of small RNAs binds mammalian Piwi proteins Nature 2006 442 199 202 10.1038/nature04917 16751776

4. Aravin AA Naumova NM Tulin AV Vagin VV Rozovsky YM Gvozdev VA Double-stranded RNA-mediated silencing of genomic tandem repeats and transposable elements in the D melanogaster germline Curr Biol 2001 11 1017 1027 10.1016/S0960-9822(01)00299-8 11470406

5. Grimson A Srivastava M Fahey B Woodcroft BJ Chiang HR King N Early origins and evolution of microRNAs and Piwi-interacting RNAs in animals Nature 2008 455 1193 1197 10.1038/nature07415 18830242 PMC3837422

6. Ozata DM Gainetdinov I Zoch A O'Carroll D Zamore PD PIWI-interacting RNAs: small RNAs with big functions Nat Rev Genet 2019 20 89 108 10.1038/s41576-018-0073-3 30446728

7. Li Y Wu X Gao H Jin JM Li AX Kim YS Piwi-interacting RNAs (piRNAs) are dysregulated in renal cell carcinoma and associated with tumor metastasis and cancer-specific survival Mol Med 2015 21 381 388 10.2119/molmed.2014.00203 25998508 PMC4534471

8. Qi T Cao H Sun H Feng H Li N Wang C piR-19166 inhibits migration and metastasis through CTTN/MMPs pathway in prostate carcinoma Aging (Albany NY) 2020 12 18209 18220 10.18632/aging.103677 32881713 PMC7585067

9. Zhang L Meng X Pan C Qu F Gan W Xiang Z piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation Cell Signal 2020 67 109501 10.1016/j.cellsig.2019.109501 31837464

10. Han H Fan G Song S Jiang Y Qian C Zhang W piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL Blood 2021 137 1603 1614 10.1182/blood.2019003764 32967010

11. Yao J Wang YW Fang BB Zhang SJ Cheng BL piR-651 and its function in 95-D lung cancer cells Biomed Rep 2016 4 546 550 10.3892/br.2016.628 27123245 PMC4840783

12. Li D Luo Y Gao Y Yang Y Wang Y Xu Y piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4 Int J Mol Med 2016 38 927 936 10.3892/ijmm.2016.2671 27431575

13. Iyer DN Wan TM Man JH Sin RW Li X Lo OS Small RNA profiling of piRNAs in colorectal cancer identifies consistent overexpression of piR-24000 that correlates clinically with an aggressive disease phenotype Cancers (Basel) 2020 12 188 10.3390/cancers12010188 PMC7016796 31940941

14. Feng J Yang M Wei Q Song F Zhang Y Wang X Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer J Cell Mol Med 2020 24 9028 9040 10.1111/jcmm.15537 32596991 PMC7417729

15. Zhou X Liu J Meng A Zhang L Wang M Fan H Gastric juice piR-1245: a promising prognostic biomarker for gastric cancer J Clin Lab Anal 2020 34 e23131 31777102 10.1002/jcla.23131 PMC7171314

16. Cheng J Guo JM Xiao BX Miao Y Jiang Z Zhou H piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells Clin Chim Acta 2011 412 1621 1625 10.1016/j.cca.2011.05.015 21616063

17. Yin J Qi W Ji CG Zhang DX Xie XL Ding Q Small RNA sequencing revealed aberrant piRNA expression profiles in colorectal cancer Oncol Rep 2019 42 263 272 31115555 10.3892/or.2019.7158

18. Weng W Liu N Toiyama Y Kusunoki M Nagasaka T Fujiwara T Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer Mol Cancer 2018 17 16 10.1186/s12943-018-0767-3 29382334 PMC5791351

19. Mai D Ding P Tan L Zhang J Pan Z Bai R PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma Theranostics 2018 8 5213 5230 10.7150/thno.28001 30555542 PMC6276099

20. Roy J Das B Jain N Mallick B PIWI-interacting RNA 39980 promotes tumor progression and reduces drug sensitivity in neuroblastoma cells J Cell Physiol 2020 235 2286 2299 10.1002/jcp.29136 31478570

21. Cordeiro A Navarro A Gaya A Diaz-Beya M Gonzalez-Farre B Castellano JJ PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma Oncotarget 2016 7 46002 46013 10.18632/oncotarget.10015 27329591 PMC5216777

22. Tan L Mai D Zhang B Jiang X Zhang J Bai R PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA Mol Cancer 2019 18 9 10.1186/s12943-019-0940-3 30636640 PMC6330501

23. Parhad SS Yu T Zhang G Rice NP Weng Z Theurkauf WE Adaptive evolution targets a piRNA precursor transcription network Cell Rep 2020 30 2672 85.e5 10.1016/j.celrep.2020.01.109 32101744 PMC7061269

24. Iwasaki YW Siomi MC Siomi H PIWI-interacting RNA: its biogenesis and functions Annu Rev Biochem 2015 84 405 433 10.1146/annurev-biochem-060614-034258 25747396

25. Thomson T Lin H The biogenesis and function of PIWI proteins and piRNAs: progress and prospect Annu Rev Cell Dev Biol 2009 25 355 376 10.1146/annurev.cellbio.24.110707.175327 19575643 PMC2780330

26. Lau NC Seto AG Kim J Kuramochi-Miyagawa S Nakano T Bartel DP Characterization of the piRNA complex from rat testes Science 2006 313 363 367 10.1126/science.1130164 16778019

27. Czech B Hannon GJ One loop to rule them all: the ping-pong cycle and piRNA-guided silencing Trends Biochem Sci 2016 41 324 337 10.1016/j.tibs.2015.12.008 26810602 PMC4819955

28. Jensen S Brasset E Parey E Roest Crollius H Sharakhov IV Vaury C Conserved small nucleotidic elements at the origin of concerted piRNA biogenesis from genes and lncRNAs Cells 2020 18 1491 10.3390/cells9061491 PMC7349650 32570966

29. Krishnan P Ghosh S Wang B Heyns M Li D Mackey JR Genome-wide profiling of transfer RNAs and their role as novel prognostic markers for breast cancer Sci Rep 2016 6 32843 10.1038/srep32843 27604545 PMC5015097

30. Keam SP Young PE McCorkindale AL Dang TH Clancy JL Humphreys DT The human Piwi protein Hiwi2 associates with tRNA-derived piRNAs in somatic cells Nucleic Acids Res 2014 42 8984 8995 10.1093/nar/gku620 25038252 PMC4132735

31. Honda S Kawamura T Loher P Morichika K Rigoutsos I Kirino Y The biogenesis pathway of tRNA-derived piRNAs in Bombyx germ cells Nucleic Acids Res 2017 45 9108 9120 10.1093/nar/gkx537 28645172 PMC5587776

32. Ha H Song J Wang S Kapusta A Feschotte C Chen KC A comprehensive analysis of piRNAs from adult human testis and their relationship with genes and mobile elements BMC Genom 2014 15 545 10.1186/1471-2164-15-545 PMC4094622 24981367

33. Zhong F Zhou N Wu K Guo Y Tan W Zhang H A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes Nucleic Acids Res 2015 43 10474 10491 10.1093/nar/gku1210 26405199 PMC4666397

34. He X Chen X Zhang X Duan X Pan T Hu Q An Lnc RNA (GAS5)/SnoRNA-derived piRNA induces activation of TRAIL gene by site-specifically recruiting MLL/COMPASS-like complexes Nucleic Acids Res 2015 43 3712 3725 10.1093/nar/gkv214 25779046 PMC4402533

35. Scott MS Ono M Yamada K Endo A Barton GJ Lamond AI Human box C/D snoRNA processing conservation across multiple cell types Nucleic Acids Res 2012 40 3676 3688 10.1093/nar/gkr1233 22199253 PMC3333852

36. Liu Y Dou M Song X Dong Y Liu S Liu H The emerging role of the piRNA/piwi complex in cancer Mol Cancer 2019 18 123 10.1186/s12943-019-1052-9 31399034 PMC6688334

37. Nishimasu H Ishizu H Saito K Fukuhara S Kamatani MK Bonnefond L Structure and function of Zucchini endoribonuclease in piRNA biogenesis Nature 2012 491 284 287 10.1038/nature11509 23064230

38. Ipsaro JJ Haase AD Knott SR Joshua-Tor L Hannon GJ The structural biochemistry of Zucchini implicates it as a nuclease in piRNA biogenesis Nature 2012 491 279 283 10.1038/nature11502 23064227 PMC3493678

39. Han BW Wang W Li C Weng Z Zamore PD Noncoding RNA. piRNA-guided transposon cleavage initiates Zucchini-dependent, phased piRNA production Science 2015 348 817 821 10.1126/science.aaa1264 25977554 PMC4545291

40. Han BW Zamore PD piRNAs Curr Biol 2014 24 R730 R733 10.1016/j.cub.2014.07.037 25137579

41. Luteijn MJ Ketting RF PIWI-interacting RNAs: from generation to transgenerational epigenetics Nat Rev Genet 2013 14 523 534 10.1038/nrg3495 23797853

42. Ross RJ Weiner MM Lin H PIWI proteins and PIWI-interacting RNAs in the soma Nature 2014 505 353 359 10.1038/nature12987 24429634 PMC4265809

43. Stein CB Genzor P Mitra S Elchert AR Ipsaro JJ Benner L Decoding the 5' nucleotide bias of PIWI-interacting RNAs Nat Commun 2019 10 828 10.1038/s41467-019-08803-z 30783109 PMC6381166

44. Zhang P Kang JY Gou LT Wang J Xue Y Skogerboe G MIWI and piRNA-mediated cleavage of messenger RNAs in mouse testes Cell Res 2015 25 193 207 10.1038/cr.2015.4 25582079 PMC4650574

45. Webster A Li S Hur JK Wachsmuth M Bois JS Perkins EM Aub and Ago3 are recruited to nuage through two mechanisms to form a Ping-Pong complex assembled by Krimper Mol Cell 2015 59 564 575 10.1016/j.molcel.2015.07.017 26295961 PMC4545750

46. Zamore PD Somatic piRNA biogenesis EMBO J 2010 29 3219 3221 10.1038/emboj.2010.232 20924396 PMC2957218

47. Sai Lakshmi S Agrawal S piRNABank: a web resource on classified and clustered Piwi-interacting RNAs Nucleic Acids Res 2008 36 D173 D177 10.1093/nar/gkm696 17881367 PMC2238943

48. Kozomara A Griffiths-Jones S miRBase: annotating high confidence microRNAs using deep sequencing data Nucleic Acids Res 2014 42 D68 73 10.1093/nar/gkt1181 24275495 PMC3965103

49. Yang Q Li R Lyu Q Hou L Liu Z Sun Q Single-cell CAS-seq reveals a class of short PIWI-interacting RNAs in human oocytes Nat Commun 2019 10 3389 10.1038/s41467-019-11312-8 31358756 PMC6662892

50. Ernst C Odom DT Kutter C The emergence of piRNAs against transposon invasion to preserve mammalian genome integrity Nat Commun 2017 8 1411 10.1038/s41467-017-01049-7 29127279 PMC5681665

51. Zhang S Pointer B Kelleher ES Rapid evolution of piRNA-mediated silencing of an invading transposable element was driven by abundant de novo mutations Genome Res 2020 30 566 575 10.1101/gr.251546.119 32238416 PMC7197473

52. Burns KH Transposable elements in cancer Nat Rev Cancer 2017 17 415 424 10.1038/nrc.2017.35 28642606

53. Payer LM Burns KH Transposable elements in human genetic disease Nat Rev Genet 2019 20 760 772 10.1038/s41576-019-0165-8 31515540

54. Castel SE Martienssen RA RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond Nat Rev Genet 2013 14 100 112 10.1038/nrg3355 23329111 PMC4205957

55. De Fazio S Bartonicek N Di Giacomo M Abreu-Goodger C Sankar A Funaya C The endonuclease activity of Mili fuels piRNA amplification that silences LINE1 elements Nature 2011 480 259 263 10.1038/nature10547 22020280

56. Sienski G Donertas D Brennecke J Transcriptional silencing of transposons by Piwi and maelstrom and its impact on chromatin state and gene expression Cell 2012 151 964 980 10.1016/j.cell.2012.10.040 23159368 PMC3504300

57. Neganova ME Klochkov SG Aleksandrova YR Aliev G Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress Semin Cancer Biol 2020 10.1016/j.semcancer.2020.07.015 32814115

58. Ninova M Chen YA Godneeva B Rogers AK Luo Y Fejes Toth K Su(var)2–10 and the SUMO pathway link piRNA-guided target recognition to chromatin silencing Mol Cell 2020 77 556 70.e6 10.1016/j.molcel.2019.11.012 31901446 PMC7007863

59. Siddiqi S Matushansky I Piwis and piwi-interacting RNAs in the epigenetics of cancer J Cell Biochem 2012 113 373 380 10.1002/jcb.23363 21928326

60. Zoch A Auchynnikava T Berrens RV Kabayama Y Schopp T Heep M SPOCD1 is an essential executor of piRNA-directed de novo DNA methylation Nature 2020 584 635 639 10.1038/s41586-020-2557-5 32674113 PMC7612247

61. Yan H Wu QL Sun CY Ai LS Deng J Zhang L piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma Leukemia 2015 29 196 206 10.1038/leu.2014.135 24732595

62. Ai L Mu S Sun C Fan F Yan H Qin Y Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation Mol Cancer 2019 18 88 10.1186/s12943-019-1011-5 30979371 PMC6461814

63. Su JF Zhao F Gao ZW Hou YJ Li YY Duan LJ piR-823 demonstrates tumor oncogenic activity in esophageal squamous cell carcinoma through DNA methylation induction via DNA methyltransferase 3B Pathol Res Pract 2020 216 152848 10.1016/j.prp.2020.152848 32051106

64. Reuter M Berninger P Chuma S Shah H Hosokawa M Funaya C Miwi catalysis is required for piRNA amplification-independent LINE1 transposon silencing Nature 2011 480 264 267 10.1038/nature10672 22121019

65. Wang W Han BW Tipping C Ge DT Zhang Z Weng Z Slicing and binding by Ago3 or Aub trigger piwi-bound piRNA production by distinct mechanisms Mol Cell 2015 59 819 830 10.1016/j.molcel.2015.08.007 26340424 PMC4560842

66. Peng L Song L Liu C Lv X Li X Jie J piR-55490 inhibits the growth of lung carcinoma by suppressing mTOR signaling Tumour Biol 2016 37 2749 2756 10.1007/s13277-015-4056-0 26408181

67. Liu X Zheng J Xue Y Yu H Gong W Wang P PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells Theranostics 2018 8 1084 1105 10.7150/thno.21740 29464001 PMC5817112

68. Yin J Jiang XY Qi W Ji CG Xie XL Zhang DX piR-823 contributes to colorectal tumorigenesis by enhancing the transcriptional activity of HSF1 Cancer Sci 2017 108 1746 1756 10.1111/cas.13300 28618124 PMC5581525

69. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931

70. Hanahan D Weinberg RA Hallmarks of cancer: the next generation Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230

71. Cheng J Deng H Xiao B Zhou H Zhou F Shen Z piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells Cancer Lett 2012 315 12 17 10.1016/j.canlet.2011.10.004 22047710

72. Li B Hong J Hong M Wang Y Yu T Zang S piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment Oncogene 2019 38 5227 5238 10.1038/s41388-019-0788-4 30890754

73. Reeves ME Firek M Jliedi A Amaar YG Identification and characterization of RASSF1C piRNA target genes in lung cancer cells Oncotarget 2017 8 34268 34282 10.18632/oncotarget.15965 28423657 PMC5470966

74. Fu A Jacobs DI Hoffman AE Zheng T Zhu Y PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly by remodeling the cancer epigenome Carcinogenesis 2015 36 1094 1102 10.1093/carcin/bgv105 26210741 PMC5006152

75. Singh G Roy J Rout P Mallick B Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers PLoS ONE 2018 13 e0190485 10.1371/journal.pone.0190485 29320577 PMC5761873

76. Spilka R Ernst C Mehta AK Haybaeck J Eukaryotic translation initiation factors in cancer development and progression Cancer Lett 2013 340 9 21 10.1016/j.canlet.2013.06.019 23830805

77. Laplante M Sabatini DM mTOR signaling in growth control and disease Cell 2012 149 274 293 10.1016/j.cell.2012.03.017 22500797 PMC3331679

78. Ediriweera MK Tennekoon KH Samarakoon SR Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance Semin Cancer Biol 2019 59 147 160 10.1016/j.semcancer.2019.05.012 31128298

79. Ma H Wang H Tian F Zhong Y Liu Z Liao A PIWI-interacting RNA-004800 is regulated by S1P receptor signaling pathway to keep myeloma cell survival Front Oncol 2020 10 438 10.3389/fonc.2020.00438 32351883 PMC7175921

80. Law PT Qin H Ching AK Lai KP Co NN He M Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma J Hepatol 2013 58 1165 1173 10.1016/j.jhep.2013.01.032 23376363

81. Burke PJ Mitochondria, bioenergetics and apoptosis in cancer Trends Cancer 2017 3 857 870 10.1016/j.trecan.2017.10.006 29198441 PMC5957506

82. Mohammad RM Muqbil I Lowe L Yedjou C Hsu HY Lin LT Broad targeting of resistance to apoptosis in cancer Semin Cancer Biol 2015 35 Suppl S78 S103 10.1016/j.semcancer.2015.03.001 25936818 PMC4720504

83. Wong RS Apoptosis in cancer: from pathogenesis to treatment J Exp Clin Cancer Res 2011 30 87 10.1186/1756-9966-30-87 21943236 PMC3197541

84. Bai L Wang S Targeting apoptosis pathways for new cancer therapeutics Annu Rev Med 2014 65 139 155 10.1146/annurev-med-010713-141310 24188661

85. Lee YJ Moon SU Park MG Jung WY Park YK Song SK Multiplex bioimaging of piRNA molecular pathway-regulated theragnostic effects in a single breast cancer cell using a piRNA molecular beacon Biomaterials 2016 101 143 155 10.1016/j.biomaterials.2016.05.052 27289065

86. Chu H Hui G Yuan L Shi D Wang Y Du M Identification of novel piRNAs in bladder cancer Cancer Lett 2015 356 561 567 10.1016/j.canlet.2014.10.004 25305452

87. Das B Roy J Jain N Mallick B Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2 Mol Carcinog 2019 58 344 357 10.1002/mc.22932 30362638

88. Das B Jain N Mallick B piR-39980 promotes cell proliferation, migration and invasion, and inhibits apoptosis via repression of SERPINB1 in human osteosarcoma Biol Cell 2020 112 73 91 10.1111/boc.201900063 31879982

89. Busch J Ralla B Jung M Wotschofsky Z Trujillo-Arribas E Schwabe P Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas J Exp Clin Cancer Res 2015 34 61 10.1186/s13046-015-0180-3 26071182 PMC4467205

90. Zhang L Meng X Li D Han X piR-001773 and piR-017184 promote prostate cancer progression by interacting with PCDH9 Cell Signal 2020 76 109780 10.1016/j.cellsig.2020.109780 32949716

91. Nishida N Yano H Nishida T Kamura T Kojiro M Angiogenesis in cancer Vasc Health Risk Manag 2006 2 213 219 10.2147/vhrm.2006.2.3.213 17326328 PMC1993983

92. Dong Y Tu R Liu H Qing G Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat Signal Transduct Target Ther 2020 5 124 10.1038/s41392-020-00235-2 32651356 PMC7351732

93. Xu X Han L Yang H Duan L Zhou B Zhao Y The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients Lung Cancer 2013 79 65 72 10.1016/j.lungcan.2012.10.005 23127338

94. Roy J Anand K Mohapatra S Nayak R Chattopadhyay T Mallick B Single nucleotide polymorphisms in piRNA-pathway genes: an insight into genetic determinants of human diseases Mol Genet Genom 2020 295 1 12 10.1007/s00438-019-01612-5 31612310

95. Toth KF Pezic D Stuwe E Webster A The piRNA pathway guards the germline genome against transposable elements Adv Exp Med Biol 2016 886 51 77 10.1007/978-94-017-7417-8_4 26659487 PMC4991928

96. Zhang W Liu H Yin J Wu W Zhu D Amos CI Genetic variants in the PIWI-piRNA pathway gene DCP1A predict melanoma disease-specific survival Int J Cancer 2016 139 2730 2737 10.1002/ijc.30409 27578485 PMC5282969

97. Chu H Xia L Qiu X Gu D Zhu L Jin J Genetic variants in noncoding PIWI-interacting RNA and colorectal cancer risk Cancer 2015 121 2044 2052 10.1002/cncr.29314 25740697

98. Banimohamad-Shotorbani B Kahroba H Sadeghzadeh H Wilson DM 3rd Maadi H Samadi N DNA damage repair response in mesenchymal stromal cells: From cellular senescence and aging to apoptosis and differentiation ability Ageing Res Rev 2020 62 101125 10.1016/j.arr.2020.101125 32683038

99. Lenart P Novak J Bienertova-Vasku J PIWI-piRNA pathway: setting the pace of aging by reducing DNA damage Mech Ageing Dev 2018 173 29 38 10.1016/j.mad.2018.03.009 29580825

100. Ladabaum U Dominitz JA Kahi C Schoen RE Strategies for colorectal cancer screening Gastroenterology 2020 158 418 432 10.1053/j.gastro.2019.06.043 31394083

101. Tanoue LT Tanner NT Gould MK Silvestri GA Lung cancer screening Am J Respir Crit Care Med 2015 191 19 33 10.1164/rccm.201410-1777CI 25369325

102. Patel S Issaka RB Chen E Somsouk M Colorectal cancer screening and COVID-19 Am J Gastroenterol 2021 116 433 434 10.14309/ajg.0000000000000970 33038127 PMC7553028

103. Nassar FJ Nasr R Talhouk R MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction Pharmacol Ther 2017 172 34 49 10.1016/j.pharmthera.2016.11.012 27916656

104. Mai D Zheng Y Guo H Ding P Bai R Li M Serum piRNA-54265 is a new biomarker for early detection and clinical surveillance of human colorectal cancer Theranostics 2020 10 8468 8478 10.7150/thno.46241 32754257 PMC7392023

105. Gu X Wang C Deng H Qing C Liu R Liu S Exosomal piRNA profiling revealed unique circulating piRNA signatures of cholangiocarcinoma and gallbladder carcinoma Acta Biochim Biophys Sin (Shanghai) 2020 52 475 484 10.1093/abbs/gmaa028 32369104

106. Chang Z Ji G Huang R Chen H Gao Y Wang W PIWI-interacting RNAs piR-13643 and piR-21238 are promising diagnostic biomarkers of papillary thyroid carcinoma Aging (Albany NY) 2020 12 9292 9310 10.18632/aging.103206 32428871 PMC7288952

107. Wang Z Yang H Ma D Mu Y Tan X Hao Q Serum PIWI-interacting RNAs piR-020619 and piR-020450 are promising novel biomarkers for early detection of colorectal cancer Cancer Epidemiol Biomark Prev 2020 29 990 998 10.1158/1055-9965.EPI-19-1148 32066615

108. Zhang H Ren Y Xu H Pang D Duan C Liu C The expression of stem cell protein Piwil2 and piR-932 in breast cancer Surg Oncol 2013 22 217 223 10.1016/j.suronc.2013.07.001 23992744

109. Qu A Wang W Yang Y Zhang X Dong Y Zheng G A serum piRNA signature as promising non-invasive diagnostic and prognostic biomarkers for colorectal cancer Cancer Manag Res 2019 11 3703 3720 10.2147/CMAR.S193266 31118791 PMC6500438

110. Zhao C Tolkach Y Schmidt D Toma M Muders MH Kristiansen G Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma World J Urol 2019 37 1639 1647 10.1007/s00345-018-2575-1 30488095

111. Wang Y Gable T Ma MZ Clark D Zhao J Zhang Y A piRNA-like small RNA induces chemoresistance to cisplatin-based therapy by inhibiting apoptosis in lung squamous cell carcinoma Mol Ther Nucleic Acids 2017 6 269 278 10.1016/j.omtn.2017.01.003 28325293 PMC5363509

112. Jacobs DI Qin Q Fu A Chen Z Zhou J Zhu Y piRNA-8041 is downregulated in human glioblastoma and suppresses tumor growth in vitro and in vivo Oncotarget 2018 9 37616 37626 10.18632/oncotarget.26331 30701019 PMC6340885

113. Huang G Hu H Xue X Shen S Gao E Guo G Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer Clin Transl Oncol 2013 15 563 568 10.1007/s12094-012-0966-0 23229900

114. Vychytilova-Faltejskova P Stitkovcova K Radova L Sachlova M Kosarova Z Slaba K Circulating PIWI-interacting RNAs piR-5937 and piR-28876 are promising diagnostic biomarkers of colon cancer Cancer Epidemiol Biomark Prev 2018 27 1019 1028 10.1158/1055-9965.EPI-18-0318 29976566

115. Iliev R Fedorko M Machackova T Mlcochova H Svoboda M Pacik D Expression levels of PIWI-interacting RNA, piR-823, are deregulated in tumor tissue, blood serum and urine of patients with renal cell carcinoma Anticancer Res 2016 36 6419 6423 10.21873/anticanres.11239 27919963

116. Zou AE Zheng H Saad MA Rahimy M Ku J Kuo SZ The non-coding landscape of head and neck squamous cell carcinoma Oncotarget 2016 7 51211 51222 10.18632/oncotarget.9979 27323410 PMC5239470

117. Muller S Raulefs S Bruns P Afonso-Grunz F Plotner A Thermann R Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer Mol Cancer 2015 14 94 10.1186/s12943-015-0358-5 25910082 PMC4417536

118. Shen S Yu H Liu X Liu Y Zheng J Wang P PIWIL1/piRNA-DQ593109 regulates the permeability of the blood-tumor barrier via the MEG3/miR-330-5p/RUNX3 Axis Mol Ther Nucleic Acids 2018 10 412 425 10.1016/j.omtn.2017.12.020 29499952 PMC5862138

119. Rounge TB Furu K Skotheim RI Haugen TB Grotmol T Enerly E Profiling of the small RNA populations in human testicular germ cell tumors shows global loss of piRNAs Mol Cancer 2015 14 153 10.1186/s12943-015-0411-4 26265322 PMC4533958

120. Gotwals P Cameron S Cipolletta D Cremasco V Crystal A Hewes B Prospects for combining targeted and conventional cancer therapy with immunotherapy Nat Rev Cancer 2017 17 286 301 10.1038/nrc.2017.17 28338065

121. Wu Q Yang Z Nie Y Shi Y Fan D Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches Cancer Lett 2014 347 159 166 10.1016/j.canlet.2014.03.013 24657660

122. Galletti G Leach BI Lam L Tagawa ST Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer Cancer Treat Rev 2017 57 16 27 10.1016/j.ctrv.2017.04.008 28527407

123. Darragh LB Oweida AJ Karam SD Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment Front Immunol 2018 9 3154 10.3389/fimmu.2018.03154 30766539 PMC6366147

124. Ramapriyan R Caetano MS Barsoumian HB Mafra ACP Zambalde EP Menon H Altered cancer metabolism in mechanisms of immunotherapy resistance Pharmacol Ther 2019 195 162 171 10.1016/j.pharmthera.2018.11.004 30439456

125. Zhang X Xie K Zhou H Wu Y Li C Liu Y Role of non-coding RNAs and RNA modifiers in cancer therapy resistance Mol Cancer 2020 19 47 10.1186/s12943-020-01171-z 32122355 PMC7050132

126. Cui C Yang J Li X Liu D Fu L Wang X Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance Mol Cancer 2020 19 58 10.1186/s12943-020-01180-y 32171304 PMC7071709

127. Iqbal MA Arora S Prakasam G Calin GA Syed MA MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance Mol Aspects Med 2019 70 3 20 10.1016/j.mam.2018.07.003 30102929

128. Peng L Jiang J Tang B Nice EC Zhang YY Xie N Managing therapeutic resistance in breast cancer: from the lncRNAs perspective Theranostics 2020 10 10360 10377 10.7150/thno.49922 32929354 PMC7482807

129. Wang K Liang C Liu J Xiao H Huang S Xu J Prediction of piRNAs using transposon interaction and a support vector machine BMC Bioinform 2014 15 419 10.1186/s12859-014-0419-6 PMC4308892 25547961

130. Li D Luo L Zhang W Liu F Luo F A genetic algorithm-based weighted ensemble method for predicting transposon-derived piRNAs BMC Bioinform 2016 17 329 10.1186/s12859-016-1206-3 PMC5006569 27578422

131. Brayet J Zehraoui F Jeanson-Leh L Israeli D Tahi F Towards a piRNA prediction using multiple kernel fusion and support vector machine Bioinformatics 2014 30 i364 i370 10.1093/bioinformatics/btu441 25161221 PMC4147894

132. Liu B Yang F Chou KC 2L-piRNA: a two-layer ensemble classifier for identifying piwi-interacting RNAs and their function Mol Ther Nucleic Acids 2017 7 267 277 10.1016/j.omtn.2017.04.008 28624202 PMC5415553

133. Liu X Ding J Gong F piRNA identification based on motif discovery Mol Biosyst 2014 10 3075 3080 10.1039/C4MB00447G 25230731

134. Boucheham A Sommard V Zehraoui F Boualem A Batouche M Bendahmane A IpiRId: integrative approach for piRNA prediction using genomic and epigenomic data PLoS ONE 2017 12 e0179787 10.1371/journal.pone.0179787 28622364 PMC5473586

135. Pian C Chen YY Zhang J Chen Z Zhang GL Li Q V-ELMpiRNAPred: Identification of human piRNAs by the voting-based extreme learning machine (V-ELM) with a new hybrid feature J Bioinform Comput Biol 2017 15 1650046 10.1142/S0219720016500463 28178889

136. Rosenkranz D Zischler H proTRAC–a software for probabilistic piRNA cluster detection, visualization and analysis BMC Bioinformatics 2012 13 5 10.1186/1471-2105-13-5 22233380 PMC3293768

137. Jung I Park JC Kim S piClust: a density based piRNA clustering algorithm Comput Biol Chem 2014 50 60 67 10.1016/j.compbiolchem.2014.01.008 24656595

138. Wang K Hoeksema J Liang C piRNN: deep learning algorithm for piRNA prediction PeerJ 2018 6 5429 10.7717/peerj.5429 PMC6078063 30083483

139. Zhang P Si X Skogerbo G Wang J Cui D Li Y piRBase: a web resource assisting piRNA functional study Database (Oxford) 2014 2014 bau110 25425034 10.1093/database/bau110 PMC4243270

140. Wang J Zhang P Lu Y Li Y Zheng Y Kan Y piRBase: a comprehensive database of piRNA sequences Nucleic Acids Res 2019 47 D175 D180 10.1093/nar/gky1043 30371818 PMC6323959

141. Yuan J Zhang P Cui Y Wang J Skogerbo G Huang DW Computational identification of piRNA targets on mouse mRNAs Bioinformatics 2016 32 1170 1177 10.1093/bioinformatics/btv729 26677964

142. Pang KC Stephen S Dinger ME Engstrom PG Lenhard B Mattick JS RNAdb 2.0—an expanded database of mammalian non-coding RNAs Nucleic Acids Res 2007 35 D178 D182 10.1093/nar/gkl926 17145715 PMC1751534

143. Tosar JP Rovira C Cayota A Non-coding RNA fragments account for the majority of annotated piRNAs expressed in somatic non-gonadal tissues Commun Biol 2018 1 2 10.1038/s42003-017-0001-7 30271890 PMC6052916

144. Rosenkranz D piRNA cluster database: a web resource for piRNA producing loci Nucleic Acids Res 2016 44 D223 D230 10.1093/nar/gkv1265 26582915 PMC4702893

145. Sarkar A Maji RK Saha S Ghosh Z piRNAQuest: searching the piRNAome for silencers BMC Genom 2014 15 555 10.1186/1471-2164-15-555 PMC4227290 24997126

146. Zhang H Ali A Gao J Ban R Jiang X Zhang Y IsopiRBank: a research resource for tracking piRNA isoforms Database (Oxford) 2018 10.1093/database/bay059 PMC6025188 29961820

147. Wu WS Huang WC Brown JS Zhang D Song X Chen H pirScan: a webserver to predict piRNA targeting sites and to avoid transgene silencing in C. elegans Nucleic Acids Res 2018 46 W43 W48 10.1093/nar/gky277 29897582 PMC6030828

148. Wu WS Brown JS Chen TT Chu YH Huang WC Tu S piRTarBase: a database of piRNA targeting sites and their roles in gene regulation Nucleic Acids Res 2019 47 D181 D187 10.1093/nar/gky956 30357353 PMC6323935

149. Xin J Du M Jiang X Wu Y Ben S Zheng R Systematic evaluation of the effects of genetic variants on PIWI-interacting RNA expression across 33 cancer types Nucleic Acids Res 2021 49 90 97 10.1093/nar/gkaa1190 33330918 PMC7797066

150. Jansson MD Lund AH MicroRNA and cancer Mol Oncol 2012 6 590 610 10.1016/j.molonc.2012.09.006 23102669 PMC5528350

151. Meng S Zhou H Feng Z Xu Z Tang Y Li P CircRNA: functions and properties of a novel potential biomarker for cancer Mol Cancer 2017 16 94 10.1186/s12943-017-0663-2 28535767 PMC5440908

152. Gou LT Dai P Yang JH Xue Y Hu YP Zhou Y Pachytene piRNAs instruct massive mRNA elimination during late spermiogenesis Cell Res 2014 24 680 700 10.1038/cr.2014.41 24787618 PMC4042167

153. Dai P Wang X Gou LT Li ZT Wen Z Chen ZG A Translation-activating function of MIWI/piRNA during mouse spermiogenesis Cell 2019 179 1566 81.e16 10.1016/j.cell.2019.11.022 31835033 PMC8139323

154. Shi S Yang ZZ Liu S Yang F Lin H PIWIL1 promotes gastric cancer via a piRNA-independent mechanism Proc Natl Acad Sci U S A 2020 117 22390 22401 10.1073/pnas.2008724117 32848063 PMC7486755

155. Li F Yuan P Rao M Jin CH Tang W Rong YF piRNA-independent function of PIWIL1 as a co-activator for anaphase promoting complex/cyclosome to drive pancreatic cancer metastasis Nat Cell Biol 2020 22 425 438 10.1038/s41556-020-0486-z 32203416